To understand what lead to the creation of Co-E1 the reader must understand: Who is Dr. Birkmayer? The following true story begins in post world war II Europe. Dr. Walther Birkmayer (Dr. Georg Birkmayer's dad) is the head physician at the Hospital for the Brain Injured in Vienna, Austria. Dr. Birkmayer is seeking an effective way to slow down mental degeneration in brain injured patients. As head physician, he monitors the health of over 3,000 brain injured patients. If you ever had a chance to listen to him, it was like every patient was an individual, directly in his care.

In 1960, with experience and experimenting, Dr. Walther Birkmayer was the first to begin treating Parkinson's disease patients with L-dopa. He found the brain neurotransmitter called dopamine was in short supply in different regions of a Parkinson's diseased brain.

L-dopa is a precursor to the brain neurotransmitter: dopamine, much in the same way beta-carodine is a precursor to vitamin A. It stood to reason: put L-dopa to therapeutic use. There was definitely a neurological effect.

In 1970, with more experience and experimenting, Drs. Walther and Georg Birkmayer further improves upon therapeutic L-dopa treatment by introducing Lisuride. Lisuride stimulates the body's ability to create the chain of events that create dopamine.

In 1975, Drs. Walther and Georg Birkmayer published their research work:

• Inhibiting the degradation of dopamine using L-deprenyl.

L-deprenyl was the next discovery in line after Lisuride. Today the most widely used drugs for treating Parkinson's disease throughout the world resulted from Dr. Birkmayer's efforts. This includes the United States usage of Sinemet.

It's sad to say, last year the N.Y. Times, Washington Post, and many other important newspapers throughout the world carried this story: Dr. Walther Birkmayer dies in his home in Vienna, Austria.

Dr. Walther Birkmayer's son:
Professor Georg D. Birkmayer, MD, Ph.D.
Thousands of Parkinson's disease patients travel to the Birkmayer Institute for Parkinson's Therapy, in Vienna, Austria, looking for a cure. And like many other degenerative diseases, there is no cure for Parkinson's disease. There won't be a cure until someone funds enough research to find the cause.

In the 1980s, Dr. Walther Birkmayer and his son, Dr. Georg Birkmayer discovered the use of nicotinamide adenine dinucleotide (also known as NADH). NADH not only slowed the onslaught of the disease, but also reduced and often reversed the devastating symptoms of the disease. They discovered NADH, something that's described in high school biology books, has tremendous benefits in the human body. And why not? NADH is found within every living cell.

Drs. Walther and Georg Birkmayer found that NADH was able to stimulate the body's own response to degenerative diseases. Wow! Think of it! NADH energizes the body to respond to its own sicknesses and diseases. When taking NADH, the brain was able to fight Parkinson's by creating the brain neurotransmitter dopamine. In tests, NADH was shown to create a six fold increase in dopamine. This was just one response to one specific degenerative disease. They knew NADH could be used to treat many other degenerative diseases.

The Birkmayers' had over 30 years experience treating Parkinson's. They found NADH was very successful. During the next 10 years, NADH was used to treated brain injuries, Alzheimer's, depression, anxiety, sleeping disorders, the mentally ill, some degenerative cardiovascular and heart diseases, the addiction to drugs or alcohol, chronic fatigue syndrome and much more.

All of these conditions are some how related. In all of these conditions the cell's mitochondria wasn't creating enough energy to heal the body. Without energy, the body was unable to keep the body healthy.

It's 1987. The first clinical study of Parkinson's disease patients received NADH intravenously. Within a year, all 450+ patients in treatment show remarkable improvement. This confirmed the Birkmayers original beliefs

. . . Who created Co-E1 part2 ?
continued on the next page